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Abstract 
Purpose: To consider the nature of cannabis-related harms under the United Kingdom’s Misuse of 
Drugs Act (MDA). Written for the specific context of this four-paper special section on 50 years of 
the MDA, it argues that the MDA may cause more harm than it prevents. 
Design/methodology/approach: An opinion piece offering a structured overview of cannabis-related 
harms under prohibition. It summarises existing evidence of the ways in which prohibition may 
exacerbate existing – and create new – harms related to the production, distribution, use and 
control of cannabis.   
Findings: The paper argues that prohibition of cannabis under the MDA may cause more harm than 
it prevents. 
Originality: It has long been argued that the MDA does not accurately or fairly reflect the harms of 
the substances it prohibits, and much existing research points to different ways in which drug 
prohibition can itself be harmful. The originality of this paper lies in bringing together these 
arguments and developing a framework for analysing the contribution of prohibition to drug-related 
harm. 
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Introduction: drug policy and harm 
One justification for prohibition of drugs is that they are harmful. There are other justifications, and 
prohibition may be better understood through perspectives of ideological censure, control, legal 
moralism or legal paternalism (see, e.g., MacCoun and Reuter, 2001). But  harm prevention is 
inherent to the UK’s 1971 Misuse of Drugs Act (MDA), which the introductory text describes as “[a]n 
act to make new provision with respect to dangerous or otherwise harmful drugs”. This paper 
focuses on this harm prevention dimension of the MDA – whether naïve or not to take this claimed 
justification of harm prevention in drug policy at face value, it seems reasonable to hope that any 
area of public policy aims for – and succeeds in – reducing harm to the public at large. 
It is accepted that drug prohibition can and does cause some harm itself, through limiting individual 
freedoms to consume drugs and through the imposition of punishment on those who break the law. 
The justification for imposing such harms under the law is that prohibition prevents more harm than 
it causes through deterring use. This position is succinctly expressed by DuPont and Voth (1995 
p.461): “A restrictive drug policy is a deterrent to drug use and helps reduce drug-related costs and 
 
 
societal problems. Although legalization or decriminalization of drugs might reduce some of the legal 
consequences of drug use, increased drug use would result in harmful consequences.” 
The logic of this position implies a utilitarian calculus: the amount of drug-related harm is dependent 
on the number of users; fewer users means less total harm. However, the calculation is more 
complicated than that. Fewer users undoubtedly means fewer people exposed to the individual 
harms related to drug use. But if the severity of those harms is increased because of prohibition then 
the total amount of harm to users may increase even if the number of users is reduced. And there is 
an assumption here that prohibition has a significant impact on the number of people using drugs: if 
it does not, then increased harm to users more readily becomes an increase in overall harm. Further, 
a calculation of total harms related to drugs should also consider harms to others: if prohibition 
increases these harms, prohibition on the grounds of harm prevention becomes even harder to 
justify. 
Numerous reports, from academics (e.g., Nutt et al., 2010), charities (e.g., RSA 2007), criminal justice 
agencies (e.g., Runciman, 2000) and official government bodies (e.g., ACMD, 2002), have argued that 
cannabis (and, in some cases, other drugs) are mis-categorised under the MDA in relation to its 
harmfulness as a substance. This paper does not seek to revisit the argument of the relative harm of 
cannabis compared to other drugs or its classification under the MDA. Instead, it seeks to overview 
the broader argument that prohibition of cannabis causes more harm than it prevents.  
The paper supports this argument by identifying the ways in which drug policy may exacerbate, 
rather than prevent, both individual and societal cannabis-related harms. It focuses on cannabis, as 
the most widely used illegal drug in the UK – and one for which the inherent harms are small (at 
least in comparison to other illegal – and legal – drugs) (Nutt et al., 2010) and, arguably, the harms 
caused by drug policy are most pronounced. However, a similar analytical framework can be applied 
to other prohibited drugs – and while the specific calculus will vary for different substances, the 
conclusion is likely to be the same: under prohibition, drug-related harms have been increased 
rather than reduced.  
The paper takes the form of a structured overview of different aspects of cannabis-related harms 
under prohibition. There is a vast literature to draw on, and the paper is necessarily selective. As 
such, it aims to be indicative rather than exhaustive – both of the range of harms considered and the 
literature consulted. Literature cited prioritises existing reviews of evidence in the different areas 
discussed. Reflecting both the limits of space, and the remit of this special section (to critique the 
MDA on its 50th anniversary) and the paper itself (a viewpoint paper), literature is also selected to 
outline the range and nature of the arguments rather than fully assess the evidence base for each of 
those arguments. There is much literature (some of it cited here) that does explore the individual 
arguments in more depth, and more evidence is amassing on how legalisation of cannabis (e.g., in 
Uruguay, Canada and a growing number of individual US states) changes its harmfulness. The central 
aim of the current paper is to try to bring the various arguments together in one article, structured 
under the categories of harms related to cannabis use, to production and distribution, and to law 
enforcement, considering which harms are inherent to cannabis and which are created or 
exacerbated by prohibition. 
Cannabis demand and supply under the MDA 
The 2019-20 sweep of the Crime Survey for England and Wales (ONS, 2020) found that 31.1% of 16–
59-year-olds reported having ever used cannabis, a figure that has remained remarkably steady 
across the last 20 years. Last-year use was reported by 7.8% of the population, a decline from the 
10.7% peak reported in 2002-03, but a continuation of a steady increase from the low-point 6.3% of 
 
 
2012-13. Comparable figures do not exist for before the 1990s, but cannabis use expanded 
significantly across the second half of the 20th Century – despite the introduction of the MDA 
(Abrams, 2008). With 2.6 million annual users 50 years after its introduction, it seems the MDA has 
had limited deterrent effect. 
Demand is predominantly from ‘recreational’ users, but increasingly includes medical users (Nutt, 
2014; APPG 2016). The expansion of medical use is fuelled, at least in part, by accumulated evidence 
of the beneficial effects of cannabis for a range of medical conditions – and the legalisation of 
medical cannabis in an increasing number of countries. Technically, cannabis was legalised for 
medical use in the UK in November 2018. In reality, the number of people with access to legally-
prescribed medical cannabis is tiny (Bone and Potter, 2021). Whether using for medical or 
recreational purposes, demand persists despite criminalisation and depends on illegal production 
and supply. 
The UK cannabis market has been valued at over £2.5 billion per annum (Snowdon, 2018). This 
lucrative market is largely in the hands of criminals incentivised by profit, although there has been a 
significant increase in small-scale cultivation by users looking to be self-sufficient and, in many cases, 
to supply small groups of friends and acquaintances without depending on the criminal market 
(Potter and Klein, 2020). In either case, under prohibition, production and supply remain entirely 
unregulated – a situation conducive to the creation rather than the prevention of harm. 
Harms related to cannabis under prohibition 
As with all drugs, cannabis is linked to a wide range of harms. Consumption poses risks to physical 
and mental health, and may also have negative impacts on users’ social and economic well-being. 
Other purported risks include developing dependency or addiction, and escalation to use of more 
harmful drugs. Cannabis markets are often linked to serious and organised crime, which harms 
society in a variety of ways. Importation of cannabis depends on overseas production, often linked 
to environmental harms and political instability in producer nations. Domestic cultivation carries its 
own environmental and situational risks, and can result in produce that increases the risks related to 
consumption. Further harms to society relate to the enforcement of prohibition, including: the 
demands placed on criminal justice and health services; the criminalisation, stigmatisation and 
alienation of the significant proportion of the population that uses cannabis; and the loss of 
potential health, economic and other benefits that could be realised if cannabis were legal. The 
following sections overview these harms in more detail, focusing particularly on how prohibition 
exacerbates the (few) harms that are inherent to cannabis itself and generates harms that would not 
otherwise exist. 
Harms related to cannabis use 
Death and physical health problems 
Preventing deaths is a strong justification for prohibition, but there is little evidence that the MDA 
prevents deaths from cannabis use. Unlike many other illegal (and legal) drugs, cannabis carries no 
risk of death by overdose (Nutt et al., 2010). There is some risk of death or serious harm (to users or 
to others) related to behaviour under the influence of cannabis: cannabis intoxication increases the 
risk of accident when driving (Sewell et al., 2009). However, increased prevalence of cannabis use 
need not mean increased prevalence of cannabis-related accidents (Ayedotte et al., 2017). 
Prohibition is neither a useful nor necessary tool for preventing deaths related to drug-impaired 
driving: drug-impaired driving and similar dangerous driving behaviour are crimes independent of 
prohibition under the MDA. 
 
 
Acute risks aside, cannabis has been linked to a range of adverse health effects (Volkow et al., 2014). 
This includes respiratory illnesses and cardiovascular problems (Gates et al., 2014; Ribeiro and Ind, 
2016; Nugent et al., 2017; National Academies of Science, Engineering and Medicine, 2017). 
However, the relationship appears more associated with the route of administration than inherent 
to cannabis itself (Russell et al., 2017). Smoking cannabis, especially if mixed with tobacco, is the 
most harmful route of administration. Prohibition arguably acts as a barrier to encouraging less 
harmful modes of consumption, although the declining popularity of tobacco smoking should help 
break the link between cannabis and tobacco.  
Mental health and addiction 
The link between cannabis and mental health problems has been of more concern in UK political 
discourse. Cannabis use has been shown to correlate with schizophrenia and other psychotic 
disorders (Manrique-Garcia et al., 2012; Moore et al., 2007) although causation is hard to establish 
(ACMD, 2008). Cannabis use does increase the risk of psychosis, especially among younger users, but 
the absolute risk remains extremely low (Hickman et al., 2009). Although cannabis is not associated 
with addiction in the same way that heroin, crack-cocaine, tobacco or alcohol are (Nutt et al., 2010), 
there has been an upsurge in cannabis users seeking treatment for problematic use (McCulloch, 
2017).  
The risks of mental health problems and addiction, where they do occur, have been largely 
attributed to the effects of tetrahydrocannabinol (THC, the main psychoactive component of 
cannabis) (Ranganathan and D’Souza, 2006; Morgan et al., 2010; Di Forti et al., 2009; Hall, 2009). 
Other cannabinoids mitigate these effects. Specifically, cannabidiol (CBD) has been demonstrated to 
have neuro-protective, anxiolytic and antipsychotic effects (Englund et al., 2013; Englund et al., 
2014; Morgan et al., 2010; Morgan and Curran, 2008; Fakhoury 2016). Prohibition makes it 
impossible to regulate to ensure a lower-risk substance, and leaves users with no way of knowing 
the potency of what they are consuming. In countries where cannabis is available legally, it has been 
possible to introduce maximum and minimum THC and CBD limits (Transform, 2018) and clear 
labelling on cannabis products (Klieger et al., 2017). 
Other drug use and criminal behaviour 
A concern often raised in support of prohibition is that cannabis presents a ‘gateway’ to using other, 
more harmful drugs. The idea that cannabis inevitably leads to the use of harder drugs has long been 
refuted (Zimmer and Morgan, 1997). Where there is a potential gateway effect, this relates more to 
overlapping markets than any psychopharmacological factors (Uhl and Krauss, 2009; Melberg et al., 
2009). This link is a direct result of prohibition. Breaking the link between ‘soft’ and ‘hard’ drug use is 
a key rationale behind the Dutch coffeeshop system. In the Netherlands, cannabis use may be higher 
than it is in the UK, but it is lower than many neighbouring European countries that do not have 
coffeeshops (Transform, 2018) and has had measurable success in separating hard and soft drug 
markets (Wouters and Korf, 2009). 
Drug use is often associated with criminal behaviour, which may be harmful to users themselves but 
also causes harm to others. The relationship is complex: it can include crimes committed by users 
while under the influence of drugs (psychopharmacological crimes), those committed to fund drug 
use (economic-compulsive crimes), and those occurring in relation to the operation of drug markets 
(systemic crimes) (Goldstein, 1985). However, these links are most evident for drugs such as heroin 
and crack-cocaine, and the drug most associated with psychopharmacological crime is alcohol 
 
 
(Bennet and Holloway, 2005). Cannabis users have been found to be no more involved in crime than 
non-users (Pedersen and Skardhamar, 2010).  
Harms related to production and distribution 
Cannabis markets around the world have undergone significant change in recent decades (Decorte 
et al., 2011). Domestic cultivation has replaced importation as the dominant source of cannabis 
(Potter and Klein, 2020). Indoor growing, utilising high-tech cultivation techniques, is linked to 
potentially more harmful cannabis products and generates environmental and situational harms and 
risks. The portion of the market that is still served by importation is linked to environmental damage 
and political instability in producer nations (UNODC, 2021). Commercial-scale cultivation and 
importation is facilitated by groups involved in other drug markets and in serious and organised 
crime. Prohibition provides these criminal networks with a significant source of revenue. 
For reasons of space, and reflecting the fact that domestic production now accounts for the majority 
of cannabis consumed in the UK, the discussion in this section will focus on harms associated with 
production and distribution within the UK. 
Harmful products 
The general trend amongst illegal cannabis producers has been to prioritise increasing THC levels, 
while breeding out (deliberately or inadvertently) neuroprotective cannabinoids such as CBD (Potter 
et al., 2018). This results in a stronger product that can bring in greater profit, but exposes users to 
greater levels of the potency-related risks outlined above. Some cannabis growers use chemical 
fertilizers, pesticides, plant growth regulators and other products, many of which are not subject to 
the same level of regulation that would apply to products explicitly marketed for agricultural crops 
intended for human consumption (Subritzky et al., 2017; Lenton et al., 2018).  Illegal producers and 
suppliers have also been reported to adulterate herbal cannabis with hairspray or glass beads to 
make it appear to be of a higher quality or weight (Randerson, 2007). Adulterated produce 
generates health risks that are not inherent in cannabis itself. Under prohibition, it is impossible to 
regulate growing practices or to monitor product quality – whether in relation to potency or purity.  
Environmental and situational harms 
Indoor production commonly employs high-tech methods including artificial lighting and automated 
irrigation systems (Potter, 2010). Commercial cannabis growing often involves illegal bypassing of 
electricity meters. Risks include fires and floods (Potter and Klein, 2020), which can cause serious 
property damage. Electricity theft results in loss of revenue to electricity suppliers, a cost passed on 
to ordinary consumers in the form of higher prices (OFGEM, 2014).  
Disposal of paraphernalia and of residual plant material can also be an environmental problem at a 
local level, with growers more likely to engage in fly-tipping than taking such materials to municipal 
waste sites (Potter and Klein, 2020). Indoor cultivation may also contribute to environmental harms 
more broadly, both through contribution to greenhouse gases from energy consumption and the 
release of volatile organic compounds into the immediate environment (Ashworth and Vizuete, 
2017).  
Links to serious and organised crime 
Criminal groups involved in cultivation, importation or distribution of cannabis may be involved in 
other drug trafficking and organised crime. Such organisations are also far more likely to engage in 
other criminal behaviour as part of their business practice, including violence and corruption. A 
 
 
Belgian study into harms associated with cannabis cultivation found “limited harms generated” 
overall, and that most harms that do exist are “generated by large-scale growers” (Paoli et al., 2015 
p.277). 
An important example here is the use of people-trafficking and forced labour. The UK’s Counter 
Human Trafficking Bureau estimated that some 3,000 Vietnamese children have been trafficked to 
Britain to serve as slave labour for criminal organisations involved in drug trafficking and cannabis 
production (Kelley and McNamara, 2015). While forced labour among illegal immigrants is an issue 
that also affects the legal agricultural industry, it becomes even harder to tackle within an industry 
that is operating underground.  
Prohibition, instead of eliminating the cannabis market, simply leaves it in the hands of criminal 
enterprises. The more supply is curbed, the more valuable the illegal product becomes, and the 
greater the potential profits – and the incentives for others to enter the market. Evidence from the 
Americas suggests that legalised medical cannabis markets across the US have undermined 
organised crime related to drug trafficking from Mexico, reducing violence and gang-related crime 
on both sides of the border (Gavrilova et al., 2017).   
The growth of domestic cultivation has also been associated with increased theft and violence 
targeting growers, where criminal groups seek to eliminate or intimidate rivals or see small-scale 
growers as targets. Stolen cannabis (and equipment) can be sold, and thieves calculate that their 
victims may not report crimes to the police for fear of being prosecuted themselves. In some cases, 
these small-scale growers retaliate with their own criminal activity, further escalating the amount of 
crime associated with growing (Potter and Klein, 2020).  
Harms related to law enforcement 
Enforcement of the MDA causes harm to those who are arrested, prosecuted and punished. Unequal 
and inconsistent application of the law exacerbates existing inequalities and undermines the 
legitimacy of the law more broadly. Further harms related to law enforcement include the loss of 
benefits that could be realised if cannabis were legal, including potential tax revenues and medical 
benefits. 
Criminalisation 
Cannabis possession accounted for 75% of all drug offences in England and Wales in 2016/17 (Allen, 
2018). While these offences have mainly resulted in warnings, fixed penalty notices and cautions, 
significant numbers are still prosecuted for cannabis possession (Shiner et al., 2018). More serious or 
multiple offences can lead to more significant criminal penalties, with associated court and prison 
costs. Supply offences, and the heavier penalties attached to them, can affect people who grow and 
distribute cannabis on a small-scale, ‘social supply’ (Potter, 2009), basis, including those growing to 
supply themselves or others for medical use, as well as those who deal cannabis for financial gain.  
Individuals prosecuted for cannabis offences face a range of negative consequences, extending 
beyond the punishment itself and damaging society at large. Even relatively mild sanctions such as 
official cautions result in a criminal record, which can have strongly negative consequences for 
future employment opportunities, finance and housing. More serious punishments, such as 
imprisonment, severely disrupt education and employment, and can cause or exacerbate mental 
health problems. Imprisonment, in effect, also punishes the families of convicted drug users; 
children grow up without parents, and households are forced into poverty by the loss of income.   
 
 
These negative consequences for drug users may be viewed as fitting punishments for criminals. It is 
therefore worth reminding ourselves what the ostensible purpose of drug law is: to minimise the 
harms caused by drugs to drug users, their families, and society as a whole. Prohibition attempts to 
achieve this, but if drug laws were enforced to the letter, every cannabis user in the country would 
face a more significant threat to their livelihoods and mental health from law enforcement than they 
would from cannabis itself. Unequal enforcement of the law avoids this scenario, but exacerbates 
social inequities facing those groups that are more likely to face criminal justice interventions for 
their cannabis use – and undermines respect for the law and the criminal justice system more 
generally. While the health, economic and societal consequences of cannabis use should not be 
ignored, they pale in comparison to the many economic and societal consequences of 
criminalisation. 
Unequal enforcement 
The vast majority of cannabis users (and those involved in cultivation and supply) never experience 
arrest. On one reading, this is clearly a good thing: processing 2.6 million annual offenders would 
clog up the criminal justice system – and have a significant impact on the functioning of society at 
large. However, the fact that only a small proportion of all cannabis offenders experience criminal 
justice intervention generates different problems. Those that are arrested are not a random sample 
of all cannabis offenders. Enforcement is unequal, and disproportionately falls on certain sections of 
society – often mirroring (and reinforcing) pre-existing social inequalities. Enforcement of cannabis-
related offences vary hugely across the UK (Allen and Kirk-Wade, 2020), and are generally higher in 
poorer parts of the country. Chances of arrest and punishment are significantly higher for BAME 
groups than for white users (Shiner et al., 2018). 
Enforcement and criminal justice system costs 
Cannabis user detection, arrests, and prosecutions are a significant drain on police time and 
resources. Formal criminal sanctions, especially imprisonment, place an additional burden on the 
criminal justice system. A cost-benefit analysis of the cannabis market in 2013 estimated that a 
legally regulated cannabis market could bring about a net benefit of £280-460 million yearly, based 
on estimates of the police, court and detention costs that would be saved (Bryan et al., 2015).  
Various British police forces consider the resources expended on cannabis policing as unacceptably 
high considering the relatively minor negative consequences of cannabis use compared to other 
crime. A trend towards de facto decriminalisation is appearing across the UK, with police forces 
including Durham, Avon and Somerset, Derbyshire, Dorset and Surrey announcing reduced efforts in 
targeting possession or growing of cannabis for personal use in recent years (Evans, 2015; Murphy, 
2016).  
Lost benefits 
The cannabis industry, if brought into the legal economy, could generate significant wealth and 
employment opportunities. A regulated cannabis market would enable the government to tax 
cannabis products and related industries. The Institute for Economic Affairs (IEA) estimated the 
potential tax revenue from this as exceeding £1 billion p.a. (Snowdon, 2018), with other recent 
estimates ranging from £0.9 billion (Bryan et al., 2015) to £3 billion (Parey and Rasul, 2020). These 




The has been a renewed interest in the medical benefits of cannabis in recent years, and over 40 
countries around the world have legalised cannabis for medical purposes. The range of conditions 
for which cannabis may be beneficial and the scientific research into medical use are too vast to 
review here, but it has been estimated that over a million people in the UK could benefit if medical 
cannabis were legally available (APPG, 2016). Medical cannabis would not only benefit many sick 
people directly, it could also reduce current burdens on the NHS. Many people use, grow and supply 
cannabis for medical purposes despite prohibition, preferring the risk of arrest and punishment to 
ongoing pain and suffering (Klein and Potter, 2018). The harms associated with criminalisation seem 
particularly cruel when applied to people who are already sick. Ironically, as we have seen, those 
who become growers or suppliers of medical cannabis to others increase their own criminal 
involvement (and, hence, risk of more serious punishment) and expose themselves to the risk of 
being victimised by criminals (Potter and Klein, 2020). 
Finally, the lost benefits of recreational use should not be overlooked. For many people, cannabis 
use is a pleasurable pastime which enhances well-being and socialising. Other reported benefits 
from recreational use include aiding creativity, enhancing sensory experiences, and promoting 
emotional, psychological and spiritual well-being. The prohibition of cannabis denies users the right 
to legally modulate their conscious state for recreational and other purposes. This might be 
justifiable in the case of an overriding public health risk, but as discussion above shows, the harms 
and risks of cannabis use do not clearly meet this standard. The pleasures of recreational cannabis 
use therefore represent a significant lost benefit to users. 
In addition, there is evidence that legalising cannabis would decrease the use of both legal 
recreational drugs such as alcohol, and the illicit recreational use of prescription drugs such as 
opioids (Reiman, 2009; Kilmer and Smart, 2018; Boehnke et al., 2016). This could result in a net 
benefit to public health, due to the higher risk profile of these currently legal substances. 
Summary and conclusions 
After 50 years of the MDA, cannabis use remains widespread: prohibition has not been successful in 
limiting use. And it is clearly arguable that the MDA has contributed to an increase rather than a 
reduction in cannabis-related harms. There are few harms intrinsic to cannabis itself; physical, 
mental-health and social harms linked to its use relate more to mode of consumption, and the 
potency and purity of cannabis used. Prohibition arguably impacts on the ability to encourage safer 
methods of use. Leaving production and supply unregulated contributes to more harmful products 
appearing on the market in the form of increased potency and greater exposure to dangerous 
additives and adulterants. Leaving the market in the hands of profit-seeking criminals exacerbates 
these problems and contributes to the social harms related to serious and organised crime.  
Meanwhile, where cannabis users (including medical users) turn to home-cultivation and social-
supply to avoid contact with the illegal market and to improve control over product quality they 
become exposed to greater risks. Production and supply are both more serious offences than 
cannabis possession, thus increasing the chance of receiving more serious sanctions. Self-, social- 
and medical-supply growers also face an increased risk of becoming victims of crime. 
Imposition of criminal penalties can lead to life-long harms stemming from the stigma of a criminal 
record beyond the immediate harms of punishment itself. This seems particularly problematic when 
applied to otherwise law-abiding citizens – and even more so when applied to those using cannabis 
to treat (often painful and debilitating) medical conditions. Law enforcement also carries a large 
economic cost. Conversely, the failure to enforce the law in the majority of cases causes different 
 
 
problems, exacerbating social inequalities and undermining the legitimacy of the criminal justice 
system and law enforcement more generally.  
Instead of reducing the risks involved with cannabis consumption, prohibition increases them. Young 
and vulnerable users are not protected – an illegal market carries no age restrictions. Heavy use is 
neither effectively discouraged nor restricted, and stigma may prevent people seeking help when it 
is needed. Cannabis products cannot be regulated to improve their safety; criminal producers are 
motivated to make them as potent and profitable as possible, often contrary to consumer 
preference. 
Finally, in outlawing cannabis, governments fail to capitalize on potential benefits to users and 
society. Recreational use, as well as medical use, can be greatly beneficial to individuals. The wealth 
creation, job creation, and tax revenue opportunities of a legal cannabis industry are forgone. 
It is established in both UK drug policy itself (HM Government, 2017) and governmental (ACMD, 
2010; MacDonald et al., 2005) and academic (Nutt et al., 2010; Ritter, 2009) discourse on drug policy 
that any analysis of drug-related harm needs to account for harms to users and harms to society. 
Under such calculations, it has repeatedly been argued that cannabis is not harmful enough to justify 
its status as a Class B controlled drug (ACMD 2008; Nutt et al., 2010). Such analysis should consider 
not just the harms inherent in the production, distribution and use of cannabis, but also the harms 
caused by drug policy itself. Doing so adds to the argument for legalisation: if prohibition is justified 
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